S12. Therapeutic Developments Session
Tracks
Room 3 | Crystal B/C
| Thursday, June 18, 2026 |
| 14:00 - 16:00 |
| Room 3 | Crystal B/C |
Details
Chairs: Marie-Claude Potier and Renata Bartesaghi
Speaker
Prof. Renata Bartesaghi
Professor Alma Mater
University of Bologna
First Panel: Treatment of cognitive deficits and regression in Down syndrome.
Dr. Jonathan Santoro
Director of Neuroimmunology
Children's Hospital Los Angeles and the Keck School of Medicine of the University of Southern California
New Frontiers: Early Industry Engagement in Rare Disease.
14:00 - 14:15
Erin Fromm
New Frotiers: Early Industry Engagement in Rare Disease
14:00 - 14:15
Dr Laurent Meijer
President & CSO
Perha Pharmaceuticals
Phase 1 clinical trial of Leucettinib-21, a DYRK1A kinase inhibitor aiming at the treatment of Down syndrome, Alzheimer’s disease, and Parkinson’s disease.
14:15 - 14:30
Dr. Floriana Costanzo
Bambino Gesù Children's Hospital, Rome
Transcranial Direct Current Stimulation to Enhance Cognition and Behavior in Down Syndrome: A Randomized, Placebo-Controlled Proof-of-Concept Study on Language Outcomes
14:30 - 14:45
Dr Marie-claude Potier
Director Of Research Cnrs
Paris Brain Institute, ICM
Second Panel: Treatment of Alzheimer’s disease in Down syndrome
Jennifer Ann Zimmer
Eli Lilly and Company
Alzheimer’s Disease in Adults with Down Syndrome: Closing the Clinical Research Gap.
14:45 - 15:00
Patrick Kesslak
Alzheon Inc.
Valiltramiprosate Reduced ARIA Rates in Phase 3 Study of APOE4/4 Subjects with Early AD: Implications to Down syndrome
15:00 - 15:15
Mr. Charlie Grieser
Alamar Biosciences
Decoding Alzheimer’s Progression and Neuroinflammation in Down Syndrome Through Ultra-Sensitive Biomarker Profiling.
15:15 - 15:30
Jack Walsh
OLINK
Accelerating impact with Thermo Fisher Olink proteomic solutions.
15:30 - 15:45
Dr Marie-claude Potier
Director Of Research Cnrs
Paris Brain Institute, ICM
Final discussion and conclusions
15:45 - 16:00
|
